P&T MEETING AGENDA: APRIL 21, 2026

COMMONWEALTH OF KENTUCKY
CABINET FOR HEALTH AND FAMILY SERVICES
DEPARTMENT FOR MEDICAID SERVICES
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING

NOTE: This special-called meeting will be held virtually via Microsoft Teams webinar.

Tuesday, April 21, 2026
1:00 P.M. to 4:00 P.M. (Eastern)

Smartphone/Web	Dial-In by Phone
Microsoft Teams **Join the meeting now** Meeting ID: 225 956 973 145 06 Passcode: hg9By9ZV **Download Teams | Join on the web**	+1 858-252-2734 (United States) Phone conference ID: 718 536 178#

AGENDA

I. Call to Order and Welcome

II. Executive Session (Upon Request)

III. Old Business

a. Approval of July 2025 Meeting Minutes
b. Approval of October 2025 Meeting Minutes
c. Approval of January 2026 Meeting Minutes
d. Presentation of Itvisma® (onasemnogene abeparvovec-brve) Clinical Criteria

IV. New Business

a. New Products to Market to be Reviewed as Single Products
   i. Palsonify™ (paltusotine) – Non-PDL
   ii. Voyxact® (sibeprenlimab-szsi) – Non-PDL
   iii. Attruby™ (acoramidis) – Non-PDL
   iv. Redemplo® (plozasiran) – Non-PDL
   v. Forzinity™ (elamipretide) – Non-PDL
   vi. Aqvesme™ (mitapivat) – Non-PDL
   vii. Pivya (pivmecillinam) – Non-PDL
   viii. Zycubo® (copper histidinate) – Non-PDL
   ix. Cardamyst™ (etripamil) – Non-PDL
   x. Myqorzo™ (aficamten) – Non-PDL

V. Therapeutic Classes with Recommended PDL Status Changes

a. Bone Resorption Suppression and Related Agents
b. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
c. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

Copyright © 2025. MedImpact Healthcare Systems, Inc.
All rights reserved.

VI. Therapeutic Classes with Recommended Structure Changes (No PDL Status Changes)

a. Colony Stimulating Factors
b. Steroids, Topical

VII. Consent Agenda

a. The following therapeutic classes have no recommended changes and may be voted on as a group under a consent agenda

• Narcotic Agonist/Antagonists • Narcotics, Fentanyl Buccal Products • Narcotics, Long-Acting • Narcotics, Short-Acting • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) • Opiate Dependence Treatments • Antihyperuricemics • Erythropoiesis Stimulating Proteins • Phosphate Binders • Sickle Cell Anemia Treatments • Thrombopoiesis Stimulating Proteins • Alpha-Glucosidase Inhibitors • Insulins and Related Agents	• Meglitinides • Metformins • Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors • Sulfonylureas • Thiazolidinediones (TZDs) • Androgenic Agents • Glucagon Agents • Growth Hormone • Pancreatic Enzymes • Progestins for Cachexia • Steroids, Oral • Uterine Disorder Treatments

VIII. Adjournment

a. Schedule of Upcoming Meetings
   i. July 28, 2026 (Note: Date Change)
   ii. October 13, 2026

To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria, please go to https://kyportal.medimpact.com/provider-documents/drug-information.

PUBLIC SPEAKERS: If you would like to speak during the public session, please complete the Speaker Request form located on the Committee Information tab under the Forms section at https://kyportal.medimpact.com/provider-documents/pt-committee.

Copyright © 2025. MedImpact Healthcare Systems, Inc.
All rights reserved.